The purpose of this project is to characterize the immunopathologic abnormalities in patients with HIV infection and to determine the mechanisms underlying these abnormalities as well as to attempt to determine a better understanding of the nature of protective immunity to HIV. These studies are predominantly performed on samples of blood or lymphoid tissues obtained from healthy controls or patients with HIV infection, generally in the context of ongoing clinical research protocols. The SCID-hu PBL mouse model is utilized in some of these studies. A major emphasis of this project is to characterize the changes in the immune systems of patients with HIV infection during the natural history of the disease and the nature of the changes seen in the context of antiretroviral therapy. A variety of approaches are taken in this part of the project. The predominant effort is focused on laboratory evaluation of lymphocyte subpopulations utilizing flow cytometry and delineation of the T cell repertoire through genetic analysis. These studies are complemented by clinical protocols designed to evaluate the ability of the immune system to launch an immune response to recall antigens such as tetanus toxoid or primary antigens such as PhiX174 or keyhole limpet hemocyanin. A variety of immunologic abnormalities have been described in patients with HIV infection. Several of these are quite unique and provide windows through which to examine the regulation of the immune response and, in particular, the role of the CD4 T lymphocyte in regulation of the immune response. In this regard, the CD8 T cell limb of the immune system of patients with HIV infection is characterized by the presence of a population of cells that express increased levels of the activation markers HLA-DR and CD38. Studies are underway utilizing differential display techniques to determine whether or not these cells have arrested at a particular stage of the cell cycle and if so, by what mechanism. Patients with HIV infection progress to AIDS at different rates. One subset of HIV infected patients, long term non-progressors, appear to have developed mechanisms that are adequate to block disease progression. These individuals represent a small fraction of the patient population, but provide a unique opportunity to study mechanisms of protective immunity to HIV. By transferring the immune systems of these patients to SCID-hu mice and then examining the endogenous expression of HIV in the mice and/or the ability of the mice to withstand superinfection with unrelated strains of HIV, one is able to characterize which elements of the immune systems of these patients may be important in the control of virus. Once these elements are characterized one is able to embark upon experiments to attempt to reproduce them in the setting of progressive infection or as strategies for prophylactic vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000585-09
Application #
6098977
Study Section
Special Emphasis Panel (LIR)
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1998
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Porter, Brian O; Shen, Jean; Kovacs, Joseph A et al. (2009) Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. AIDS 23:2015-9
Sereti, Irini; Sklar, Peter; Ramchandani, Meena S et al. (2007) CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. J Infect Dis 196:677-83
Nishimura, Yoshiaki; Igarashi, Tatsuhiko; Buckler-White, Alicia et al. (2007) Loss of naive cells accompanies memory CD4+ T-cell depletion during long-term progression to AIDS in Simian immunodeficiency virus-infected macaques. J Virol 81:893-902
Sakamoto, Norihisa; Tsuji, Kazuhide; Muul, Linda M et al. (2007) Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood 110:501-8
Igarashi, Tatsuhiko; Iyengar, Ranjini; Byrum, Russel A et al. (2007) Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques. J Virol 81:11549-52
Henry, W Keith; Tebas, Pablo; Lane, H Clifford (2006) Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. JAMA 296:1523-5
Read, Sarah W; Higgins, Jeanette; Metcalf, Julia A et al. (2006) Decreased CD127 expression on T Cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy. J Acquir Immune Defic Syndr 42:537-44
Brann, Terrence W; Dewar, Robin L; Jiang, Min-Kan et al. (2006) Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness. J Virol 80:6136-45
Lempicki, R A; Polis, M A; Yang, J et al. (2006) Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 193:1172-7
Youle, Mike; Emery, Sean; Fisher, Martin et al. (2006) A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK-Vanguard Study. PLoS Clin Trials 1:e3

Showing the most recent 10 out of 38 publications